<DOC>
	<DOCNO>NCT01341795</DOCNO>
	<brief_summary>Type 2 diabetes become major global health problem . Currently , metformin use first-line therapy combination lifestyle change , sitagliptin add metformin case insufficient glycemic control metformin alone , fixed-dose combination sitagliptin metformin available . In clinical practice , inter-individual variation response sitagliptin metformin treatment commonly find , may reflect inter-patient difference disposition medication . Sitagliptin metformin know substrate transporter ( P-gp , OAT3 , OCT1 OCT2 ) functional variation transporter report . This study design clarify effect transporter variant response sitagliptin metformin type 2 DM patient .</brief_summary>
	<brief_title>Genetic Variation Transporters Hypoglycemic Agents</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Newly Diagnosed Type 2 Diabetes Patients 2080 year old Taking sitagliptin metformin 3 month Taking oral hypoglycemic agent Taking medication induce inhibit transporter</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Newly diagnose type 2 diabetes patient</keyword>
</DOC>